Vanda Pharmaceuticals | VNDA - Fremdkapital





Fremdkapital Veränderung Datum
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
Akebia Therapeutics USD 24.75M 11.64M 2026-06
Alnylam Pharmaceuticals USD 2.47B 6.56M 2026-06
Arrowhead Research USD 824.07M 401.34M 2026-06
AstraZeneca USD 26.01B 46M 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Eli Lilly USD 47.86B 8.49B 2026-06
Enanta Pharmaceuticals USD 0 0 2024-12
Halozyme Therapeutics USD 1.94B 1.79M 2026-06
Heron Therapeutics USD 140.64M 975K 2025-12
Insmed USD 543.51M 1.3M 2026-06
J&J USD 37.34B 183M 2026-06
Lexicon Pharmaceuticals USD 49.68M 276K 2026-03
Ligand Pharmaceuticals USD 446.9M 704K 2026-03
Merck USD 51.08B 4.41B 2026-06
Minerva Neurosciences USD 0 86.58M 2024-09
Moderna USD 597M 6M 2026-06
Novartis USD 37.45B 7.86B 2026-03
Pfizer USD 60.5B 70M 2026-06
PTC Therapeutics USD 535.52M 248.58M 2026-06
Puma Biotechnology USD 10.87M 222K 2025-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 14.65B 806M 2026-06
Takeda JPY 4.42T 50.32B 2026-06
Teva Pharmaceutical Industries USD 12.09B 1.92B 2026-06
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12
Veracyte USD 0 0 2025-03